« Previous Next » The Journal of Allergy and Clinical Immunology
Volume 121, Issue 1 , Pages 72-80.e3 , January 2008

Lung function, respiratory symptoms, and the menopausal transition

Francisco Gómez Real, MD
- Department of Gynecology and Obstetrics, Haukeland University Hospital, Bergen, Norway
- Centre de Recerca en Epidemiologia Ambiental (CREAL)–Institut Municipal d'Investigació Mèdica (IMIM-IMAS), Barcelona, Spain
- Respiratory Research Group, Institute of Medicine, University of Bergen, Bergen, Norway
- Reprint requests: Francisco Gómez Real, MD, Department of Gynecology and Obstetrics, Haukeland University Hospital, 5021 Bergen, Norway.
Cecilie Svanes, MD, PhD
- Centre de Recerca en Epidemiologia Ambiental (CREAL)–Institut Municipal d'Investigació Mèdica (IMIM-IMAS), Barcelona, Spain
- Respiratory Research Group, Institute of Medicine, University of Bergen, Bergen, Norway
- Department of Thoracic Medicine, Haukeland University Hospital, Bergen, Norway
Ernst Reidar Omenaas, MD, PhD
- Respiratory Research Group, Institute of Medicine, University of Bergen, Bergen, Norway
- Department of Thoracic Medicine, Haukeland University Hospital, Bergen, Norway
- Centre for Clinical Research, Haukeland University Hospital, Bergen, Norway
Josep Maria Antò, MD, PhD
- Centre de Recerca en Epidemiologia Ambiental (CREAL)–Institut Municipal d'Investigació Mèdica (IMIM-IMAS), Barcelona, Spain
- Departament de Ciencies Experimentals i de la Vida-Universitat Pompeu Fabra (UPF), Barcelona, Spain
Estel Plana, MSc
- Centre de Recerca en Epidemiologia Ambiental (CREAL)–Institut Municipal d'Investigació Mèdica (IMIM-IMAS), Barcelona, Spain
- Departament de Ciencies Experimentals i de la Vida-Universitat Pompeu Fabra (UPF), Barcelona, Spain
Deborah Jarvis, MD
- Department of Public Health Sciences, Imperial College, London, United Kingdom
Christer Janson, MD, PhD
- Department of Medical Sciences: Respiratory Medicine and Allergology, Uppsala University, Uppsala, Sweden
Françoise Neukirch, MD, PhD
- Epidémiologie des Maladies Respiratoires, INSERM U700, Faculté de Médecine Xavier Bichat, Paris, France
Elisabeth Zemp, MD, PhD
- Institute of Social and Preventive Medicine, University of Basel, Basel, Switzerland
Julia Dratva, MD, PhD
- Institute of Social and Preventive Medicine, University of Basel, Basel, Switzerland
Matthias Wjst, MD, PhD
- Molecular Epidemiology, GSF National Research Center for Environment and Health, Neuherberg, Germany
Knut Svanes, MD, PhD
- Institute of Surgery, Haukeland University Hospital, Bergen, Norway
Bénédicte Leynaert, MSc, PhD
- Epidémiologie des Maladies Respiratoires, INSERM U700, Faculté de Médecine Xavier Bichat, Paris, France
Jordi Sunyer, MD, PhD
- Centre de Recerca en Epidemiologia Ambiental (CREAL)–Institut Municipal d'Investigació Mèdica (IMIM-IMAS), Barcelona, Spain
- Departament de Ciencies Experimentals i de la Vida-Universitat Pompeu Fabra (UPF), Barcelona, Spain

Received 27 June 2007 ,Revised 23 August 2007 ,Accepted 27 August 2007.

A, OR for the associations between amenorrhea (≥6 months) and 3 or more respiratory symptoms among 1274 women aged 45 to 56 years by country (P_{heterogeneity} = .232). B, Adjusted differences for the as

A, OR for the associations between amenorrhea (≥6 months) and 3 or more respiratory symptoms among 1274 women aged 45 to 56 years by country (P_{heterogeneity} = .232). B, Adjusted differences for the associations between amenorrhea (≥6 months) and FEV₁ among 1120 women aged 45 to 56 years by country (P_{heterogeneity} = .384). For each center, horizontal lines indicate 95% CIs. For the combined estimates, the diamonds indicate 95% CIs from model, with country as random effect. The size of each square is proportional to the sample size. UK, United Kingdom; USA, United States of America.
- Full-Size Image
- Download to PowerPoint
GAM curves showing the prevalence of 3 or more respiratory symptoms (A), the level of FEV1 (B), and the level of FVC (C), all 3 according to age in women with regular menstruation or amenorrhea for 10

GAM curves showing the prevalence of 3 or more respiratory symptoms (A), the level of FEV₁ (B), and the level of FVC (C), all 3 according to age in women with regular menstruation or amenorrhea for 1082 (Fig 2, A) and 1079 (Fig 2, B and C) women aged 45 to 56 years with complete data adjusted for height, BMI, and smoking. The thicker blue line at the bottom of each graph consists of individual crosses—one cross for each observation.
- Full-Size Image
- Download to PowerPoint

F.G.R. was supported exclusively by the Norwegian Research Council (grant NFR 161299/V50). European Community Respiratory Health Survey (ECRHS) II was supported by the European Commission, as part of their Quality of Life program. Bodies funding the local studies in ECRHS II are listed in Appendix 1 in the Online Repository at www.jacionline.org. The European Commission supported the transports of serum for hormones measurement to Paris. Hormones measures were funded by the local budget of the ECRHS Paris team, INSERM U700, Epidemiology, with further support from the Comité National contre les Maladies Respiratoires (CNMR) and the Centre d'Investigation Clinique (CIC), Bichat Hospital.

Disclosure of potential conflict of interest: E. R. Omenaas has received grant support from the Norwegian Research Council. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(07)01658-2

doi: 10.1016/j.jaci.2007.08.057

« Previous Next » The Journal of Allergy and Clinical Immunology
Volume 121, Issue 1 , Pages 72-80.e3 , January 2008